Skip to main content

Drug Interactions between Hepzato and sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

melphalan SARS-CoV-2 (COVID-19) NVX-CoV2373 vaccine, recombinant

Applies to: Hepzato (melphalan) and sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant

If you are currently being treated or have recently been treated with melphalan, you should let your doctor know before receiving SARS-CoV-2 (COVID-19) NVX-CoV2373 vaccine, recombinant. Depending on the dose and length of time you have been on melphalan, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of melphalan therapy. If you have recently been vaccinated with SARS-CoV-2 (COVID-19) NVX-CoV2373 vaccine, recombinant, your doctor may choose to postpone treatment with melphalan for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer